Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Liver cirrhosis is a progressive disease characterized by loss of functional hepatocytes that
substantially affects drug pharmacokinetics. Rocuronium onset time is longer and recovery
time from it is prolonged in cirrhotic patients than in those with normal liver function.
This randomized controlled study is designed to compare the pharmacodynamic profiles of
sugammadex and neostigmine when used for the antagonism of moderate degree of
rocuronium-induced neuromuscular block in cirrhotic patients undergoing liver resection and
in patients with preoperative normal liver functions undergoing liver resection.